Year: 2017
Type: article
Abstract: The increasing prevalence of type 2 diabetes (T2D) and associated morbidity and mortality emphasizes the need for a more complete understanding of the mechanisms mediating glucose homeostasis to accelerate the identification of new medications. Recent reports indicate that the obesity medication lorcaserin, a 5-hydroxytryptamine (5-HT, serotonin) 2C receptor (5-HT2CR) agonist, improves glycemic control in association with weight loss in obese patients with T2D. Here we evaluate whether lorcaserin has an effect on glycemia without body weight loss and how this effect is achieved. Murine models of common and genetic T2D were utilized to probe the direct effect of lorcaserin on glycemic control. Lorcaserin dose-dependently improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body weight. Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin's glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin's therapeutic brain circuit, we examined the receptor target of POMC peptides. We demonstrate that lorcaserin requires functional melanocortin4 receptors on cholinergic preganglionic neurons (MC4RChAT) to exert its effects on glucose homeostasis. In contrast, MC4RChAT signaling did not impact lorcaserin's effects on feeding, indicating a divergence in the neurocircuitry underpinning lorcaserin's therapeutic glycemic and anorectic effects. Hyperinsulinemic-euglycemic clamp studies reveal that lorcaserin reduces hepatic glucose production, increases glucose disposal and improves insulin sensitivity. These data suggest that lorcaserin's action within the brain represents a mechanistically novel treatment for T2D: findings of significance to a prevalent global disease.
Source: Molecular Metabolism
Authors: Luke K. Burke, Emmanuel Ogunnowo-Bada, Teodora Georgescu, Claudia Cristiano, Pablo B. Martinez de Morentin, Lourdes Valencia Torres, Giuseppe D'Agostino, Christine Riches, Nicholas Heeley, Yue Ruan, Marcelo Rubinstein, Malcolm J. Low, Martin G. Myers, Justin J. Rochford, Mark L. Evans, Lora K. Heisler
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,673
Awards: Delineation of discrete brain circuitry regulating obesity and type 2 diabetes in mice., Delineating the regulation and function of gamma-synuclein in adipocyte lipid metabolism, Resolving a novel brain circuit controlling appetite and body weight, Function of brainstem brain-derived neurotrophic factor (Bdnf) in food choice, Brain Glucokinase and Blood Glucose: A Novel Therapeutic Target for Type 2 Diabetes?, G2988425220, Proopiomelanocortin gene expression and obesity, Neurochemistry/physiology of proopiomelancortin neurons, Accelerating Discovery: New integrated approaches to uncover the brain’s regulation of body weight, Delineation of the role of brainstem pro-opiomelanocorin neurons in energy balance, Defining the Role of the Human Lipodystrophy Protein Seipin in Adipose Tissue Development and Metabolic Disease., Institute of Metabolic Science., Delineation of brain-derived-neurotropic factor (BDNF) neurons modulating energy balance., Metabolic consequence of in vivo modulation of discrete serotonergic pathways., Institute of Metabolic Science., Delineation of a brain circuit regulating energy expenditure to impact body weight, Molecular Mechanisms of Leptin Receptor/Jak2 Action, G5602389019, Neurochemistry/Physiology of Proopiomelanocortin Neurons, G677005099, G8458495882, Role of the Lateral Hypothalamic Area in Leptin Action, G9000093744, G9000107812, Michigan Diabetes Research Center (MDRC), Molecular and Neural Mechanisms of Leptin Action
OpenAlex ID: W2737160318
